Products for Research Use Only

Nilotinib (hydrochloride)

CAT: 0804-HY-10159BSize: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-10159BSize:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Nilotinib (AMN107) hydrochloride is an orally active Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity and can be used in studies of chronic myelogenous leukaemia[1][2][3].
CAS Number
923288-95-3
Product Name Alternative
AMN107 (hydrochloride)
UNSPSC
12352005
Hazard Statement
H315-H319-H360
Target
Autophagy; Bcr-Abl
Type
Reference compound
Related Pathways
Autophagy; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/nilotinib-hydrochloride.html
Solubility
10 mM in DMSO
Smiles
O=C(NC1=CC(C(F)(F)F)=CC(N2C=C(C)N=C2)=C1)C3=CC=C(C)C(NC4=NC=CC(C5=CC=CN=C5)=N4)=C3.[H]Cl
Molecular Formula
C28H23ClF3N7O
Molecular Weight
565.98
Precautions
P264-P280-P302+P352-P305+P351+P338-P362+P364-P405-P501
References & Citations
[1]Weisberg E, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of BCR-ABL+ leukemias. Blood. 2007 Mar 1;109 (5) :2112-20.|[2] Sako H, et al. Antitumor effect of the tyrosine kinase inhibitor Nilotinib on gastrointestinal stromal tumor (GIST) and Imatinib-resistant GIST cells. PLoS One. 2014 Sep 15;9 (9) :e107613.|[3]Meirson T, et al. Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors. Oncotarget. 2018 Apr 24;9 (31) :22158-22183.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
Launched